newsfilter
← Earnings
Earnings Releases·

Ovid Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue was $0 for Q3 2026 versus $132,000 in Q3 2025; net loss widened to $20.8 million ($0.10/share) from $12.2 million ($0.17/share) year-over-year, driven by a 166% increase in R&D expenses to $15.7 million.
  • Balance sheet strengthened significantly with cash, equivalents, and marketable securities rising to $161.4 million as of September 30, 2026, from $90.4 million at year-end 2025, extending financial runway into 2029.
  • Strategic progress includes assigning global rights to Soticlestat to a new Perceptive Advisors entity for up to $294.5 million in milestones and low- to mid-single-digit royalties.
  • Future outlook targets multiple 2027 clinical readouts, including top-line data for OV329 photosensitivity and OV4071 Phase 1 studies in Q1 2027, and the initiation of a pediatric OV329 study before year-end 2026.
Company
OVID THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology